Organs from deceased donors with suspected false-positive HIV screening tests were generally discarded due to the chance that the test was truly positive. However,
| INTRODUC TI ON
The HOPE (HIV Organ Policy Equity) Act allows for HIV-infected (HIV+) donor organs to be used for transplantation in HIV+ recipients under research protocols.
1,2 The use of organs from HIV+ donors could provide a benefit for HIV+ transplant candidates who face higher mortality and lower access to transplantation compared to HIV-noninfected (HIV−) counterparts. [3] [4] [5] [6] In addition, HIV+ donor to HIV+ recipient (HIV D+/R+) transplantation may have a public health benefit by expanding the overall donor pool. at risk for recent acquisition of HIV, hepatitis B (HBV), and hepatitis C (HCV). 12,13 HIV Ab and NAT screening assays are designed to maximize sensitivity and specificity, but both have a small risk of incorrectly identifying HIV-noninfected individuals as HIV+, that is, a false-positive result. In current practice in deceased donor evaluation, there may be insufficient time for confirmation of suspected false-positive HIV screening tests. 14, 15 Therefore, prior to the HOPE Act, organs from deceased donors with a suspected false-positive HIV test were not routinely used for transplantation.
The goal of this study was to describe the details of the suspected false-positive donor cases in which organs were used for transplant under HOPE Act research protocols and to estimate the annual number of potential donors with false-positive HIV screening tests.
| ME THODS

| Study design
Pursuant to the HOPE Act, we are conducting a prospective co- Table 2 ). Among these, one had been in lockup, jail, prison, or a juvenile correctional facility for more than 72 hours in the preceding 12 months. Two had no specific behavioral risk factor documented but were categorized as increased infectious risk donors by the OPO.
| Recipients of HIV D+/R + transplants
| HIV testing
All 10 suspected false-positive donors underwent HIV Ab and NAT testing using FDA-approved, -licensed, or -cleared assays for donor screening (Table 1) . 16 Among the 10, 8 were HIV Ab+/NAT− and 2
were HIV Ab−/NAT+ (Tables 2 and 3 (Table 3) . Confirmatory testing was performed by both the OPO and the HOPE in Action laboratory in 9 of 10 cases. In one HIV Ab−/NAT+ case, the confirmatory qPCR testing was performed only by the HOPE in Action laboratory. Results of the confirmatory testing were available at the time of donor organ recovery in 50% (5 of 10) of cases. In 5 cases, the true infection status of the donor was unknown at the time of organ recovery. Five donors had both kidneys and liver used for transplant; three donors had 2 kidneys used;
one donor was kidney only and one donor was liver only.
TA B L E 1 FDA-approved, -licensed, or -cleared HIV screening tests for donors of human cells, tissues, and cellular and tissue-based products. The HIV screening tests listed here represent the assays currently used by OPOs for organ donor screening. 
| Transplants using organs from HIV-suspected false-positive donors
Organs from the 10 false-positive donors were used for trans- 
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